Education
About Us
Working with TipRanks
Follow Us
QQQS - ETF AI Analysis
Top Page
Invesco NASDAQ Future Gen 200 ETF (QQQS)
Rating:55Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains this year, reflecting positive momentum in its holdings.
Low Expense Ratio
With a competitive expense ratio, the fund allows investors to keep more of their returns compared to higher-cost alternatives.
Health Care and Technology Focus
The ETF is heavily weighted in Health Care and Technology sectors, which are often associated with innovation and growth potential.
Negative Factors
Over-Concentration in U.S. Market
The ETF is almost entirely focused on U.S. companies, limiting diversification across global markets.
Underperforming Holdings
Several top holdings, such as Omeros and Xencor, have shown weak performance, which could drag on overall returns.
Sector Concentration Risk
Nearly half of the fund is allocated to Health Care, making it vulnerable to sector-specific downturns.
QQQS vs. SPDR S&P 500 ETF (SPY)
AUM12.09M
RegionNorth America
Expense Ratio0.20%
Beta1.41
IssuerInvesco
Inception DateOct 13, 2022
Dividend Yield1.73%
Asset ClassEquity
Index TrackedNasdaq Innovators Completion Cap Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,697
30 Day Avg. Volume7,892
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
54.82Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering198
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
QQQS Summary
The Invesco NASDAQ Future Gen 200 ETF (QQQS) is an investment fund that focuses on 200 innovative small and mid-sized companies within the NASDAQ ecosystem. It aims to capture growth potential from emerging businesses that are not part of the larger NASDAQ-100 index. The ETF includes companies like uniQure and Navitas Semiconductor, which are involved in cutting-edge industries such as healthcare and technology. Investors might consider QQQS for its focus on growth and diversification, offering exposure to up-and-coming market leaders. However, new investors should be aware that the ETF is heavily weighted in healthcare and technology sectors, making it sensitive to changes in these industries.
How much will it cost me?The expense ratio for the Invesco NASDAQ Future Gen 200 ETF (QQQS) is 0.2%, which means you’ll pay $2 per year for every $1,000 invested. This is slightly higher than the average for passively managed ETFs because it focuses on a niche group of innovative small and mid-cap companies, requiring more specialized management.
What would affect this ETF?The QQQS ETF, with its focus on innovative small and mid-cap U.S. companies, could benefit from advancements in technology and healthcare, sectors that make up a significant portion of its holdings. However, it may face challenges if interest rates rise, as smaller companies often struggle with higher borrowing costs, or if economic conditions weaken, which could impact consumer spending and industrial growth. Regulatory changes in healthcare or technology could also influence the performance of its top holdings.
QQQS Top 10 Holdings
The Invesco NASDAQ Future Gen 200 ETF (QQQS) leans heavily into health care and technology, with over 80% of its portfolio concentrated in these sectors. Rising names like CytomX Therapeutics and Lumentum Holdings are giving the fund a boost, thanks to strong technical momentum and promising growth narratives. However, lagging stocks like Personalis and Xencor are holding back performance, weighed down by financial instability and valuation concerns. With its focus on small and mid-cap U.S. innovators, QQQS offers a bold bet on emerging players, though the mixed results suggest a bumpy ride for investors chasing future growth.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Ventyx Biosciences | 1.85% | $225.36K | $713.59M | 273.13% | 41 Neutral | |
| Canadian Solar | 1.23% | $150.25K | $1.82B | 118.78% | 54 Neutral | |
| Lumentum Holdings | 1.09% | $132.67K | $23.05B | 273.88% | 61 Neutral | |
| Arrowhead Pharmaceuticals | 1.06% | $129.38K | $7.16B | 102.46% | 57 Neutral | |
| Omeros | 1.04% | $126.04K | $687.03M | -14.62% | 40 Underperform | |
| Personalis | 0.98% | $118.79K | $952.87M | 170.28% | 57 Neutral | |
| Nektar Therapeutics | 0.97% | $118.36K | $1.33B | 281.34% | 54 Neutral | |
| Xencor | 0.95% | $115.26K | $1.24B | -32.34% | 57 Neutral | |
| CytomX Therapeutics | 0.93% | $113.55K | $725.18M | 303.77% | 66 Neutral | |
| Ionis Pharmaceuticals | 0.86% | $105.07K | $13.40B | 131.54% | 58 Neutral |
QQQS Technical Analysis
Positive
―
Price Trends
33.85
Positive
31.49
Positive
27.95
Positive
Market Momentum
-0.04
Negative
59.00
Neutral
98.07
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 33.29, equal to the 50-day MA of 33.85, and equal to the 200-day MA of 27.95, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 59.00 is Neutral, neither overbought nor oversold. The STOCH value of 98.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QQQS.
QQQS Peer Comparison
Comparison Results
Performance Comparison
QQQS
Invesco NASDAQ Future Gen 200 ETF
34.76
5.18
17.51%
OASC
OneAscent Small Cap Core ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
ASCE
Allspring SMID Core ETF
―
―
―
TMFX
Motley Fool Next Index ETF
―
―
―
HSMV
First Trust Horizon Managed Volatility Small/Mid ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents